The Bank of Japan's Rate Hike Fails to Halt Yen's Decline, Approaching a 40-Year Low
BlockBeats News, June 19th, according to Reuters, despite the Bank of Japan raising interest rates to the highest level in 31 years last week and the Japanese Ministry of Finance intervening in the foreign exchange market multiple times this year, the yen against the dollar still hovers near a nearly 40-year low. On Friday, the dollar against the yen was at 161.12, not far from the two-year high touched earlier.
The newly appointed Federal Reserve Chair, Kevin Warsh, hawkish stance continues to push up the dollar, while Japan's core inflation has been below the Bank of Japan's 2% target for the fourth consecutive month, weakening market expectations of further rate hikes. At the same time, Japanese Prime Minister Taro Aso's fiscal spending plan has also raised concerns in the market about the fiscal situation.
DBS Bank stated that after the Bank of Japan raised interest rates this week, short yen positions in the market have not been significantly covered, and Japan's tolerance for yen depreciation has almost reached its limit. The market expects that when the dollar against the yen approaches the 161.95 level, the Japanese Ministry of Finance may intervene in the exchange rate again. Meanwhile, CME FedWatch data shows that the probability of a 25 basis points rate hike by the Fed in July has risen to 38.5%, a significant increase from 8% a week ago, further strengthening expectations of a strong dollar.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BAE Systems wins Lockheed Martin contract to supply electronic warfare systems for F-35 jets
BAE Systems won a Lockheed Martin contract to supply electronic warfare systems for F-35 Lightning II fighter jets. Order covers production deliveries for F-35 Lots 20-22. Deal also includes retrofit systems to modernize older aircraft in the global F-35 fleet. BAE Systems has delivered more than 1,500 F-35 electronic warfare systems to date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BAE Systems plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061000PR_NEWS_USPR_____NE64821) on October 06, 2026, and is solely responsible for the information contained therein.
Japanese Yen: Range trade holds against US Dollar as Fed path questioned – Rabobank
BUZZ-GEO Group shares rise after completing $650 million debt refinancing
On October 6, shares of prison operator GEO Group (GEO.N) rose 2.6% in premarket trading to $33.19. The company conducted a debt refinancing, redeeming $650 million in senior secured notes due in 2029. Its $550 million revolving credit facility maturity was extended to July 2031. Earlier this week, the company agreed to sell its ICE processing center complex in Adelanto, California for $950 million. The company also recently increased its share repurchase authorization to $1.25 billion. As of the close of the previous trading day, the company's share price had more than doubled this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Crypto prices
More
